Editas Medicine (EDIT) Other financing activities (2016 - 2025)

Editas Medicine (EDIT) has reported Other financing activities for 10 consecutive years, with $228000.0 the latest figure, recorded in Q2 2025.

• In Q2 2025, Other financing activities rose 75.38% year-over-year to $228000.0; the TTM figure through Sep 2025 stood at $496000.0 (down 38.46% YoY), while the FY2024 annual figure was $590000.0, down 35.8% from the prior year.
• Other financing activities retreated to $228000.0 in Q2 2025 per EDIT's latest filing, from $268000.0 in the prior quarter.
• Across five years, Other financing activities topped out at $16.6 million in Q2 2021 and bottomed at $130000.0 in Q2 2024.
• Historically, Other financing activities has averaged $2.6 million across 5 years, with a median of $430000.0 in 2021.
• Annual changes were most pronounced in 2021 — Other financing activities surged 293.9% — and 2022, when it slumped 99.1%.
• Editas Medicine's Other financing activities stood at $430000.0 in 2021, then jumped by 42.33% to $612000.0 in 2022, then slipped by 20.92% to $484000.0 in 2023, then sank by 44.63% to $268000.0 in 2024, then slipped by 14.93% to $228000.0 in 2025.
• Business Quant data shows EDIT's Other financing activities at $228000.0 in Q2 2025, $268000.0 in Q4 2024, and $130000.0 in Q2 2024.